Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANOC-001/002/003 TCR-modified T-cell therapy master protocol in advanced pancreatic ductal adenocarcinoma
NL-OMON58687Phase 2Recruiting
- Sponsor
- Anocca
- Start
- Aug 2025
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, HLA-matched TCR-T → TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ANOC-001, ANOC-002 and ANOC-003 in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Anocca. Primary endpoints: Dose-limiting toxicities, Adverse events and 2 more. Started Aug 2025; status: recruiting.
02
Drugs
ANOC-001ANOC-002ANOC-003
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON58687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58687.